Related Experiment Video
Updated: Sep 17, 2025
06:35
Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres
Published on: February 2, 2015
17.3K
Circulating miRNAs in Graves' ophthalmopathy: a systematic review
Evangelia Syrakouli1, Georgios Geropoulos2, Styliani Laskou1
13rd Department of Surgery, School of Medicine, Aristotle University of Thessaloniki, "AHEPA" University Hospital, Thessaloniki, Greece.
Endocrine
|June 28, 2025
Summary
MicroRNAs (miRNAs) show potential as biomarkers for diagnosing Graves' ophthalmopathy (GO) and predicting treatment response. Further research is needed to confirm their clinical utility in managing GO patients.
Area of Science:
- Endocrinology
- Molecular Biology
- Ophthalmology
Background:
- Graves' ophthalmopathy (GO) impacts up to 40% of Graves' disease patients.
- Identifying biomarkers is crucial for targeted GO management and predicting treatment response.
- Circulating microRNAs (miRNAs) are being explored as potential diagnostic and prognostic indicators.
Purpose of the Study:
- To investigate circulating miRNAs in serum or plasma as potential biomarkers for GO diagnosis and prognosis.
- To identify miRNAs that can predict treatment response in GO patients.
Main Methods:
- A systematic literature search was performed across MEDLINE, EMBASE, and Cochrane databases.
- Included studies assessed miRNA expression in serum, plasma, or CD4+ T cells of human participants with or without GO.
- Eleven studies involving 195 patients met the eligibility criteria.
Main Results:
- Analysis of 6567 miRNAs revealed significant differences in GO patients.
- Seven miRNAs were upregulated and four downregulated in GO patients.
- Specific miRNA expression patterns correlated with response or resistance to glucocorticoid therapy.
Conclusions:
- MicroRNAs show promise as biomarkers for early GO diagnosis, prognosis, and predicting glucocorticoid therapy response.
- Correlation exists between serum/plasma miRNA expression and GO presence, activity, and treatment response.
- Further clinical studies are required to validate the predictive value of miRNAs in clinical practice.
